Swiss drugmaker Novartis will invest up to an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said on Sunday.   Novartis last year invested $35 million in the company for a 15 percent stake, in a deal that could reach $600 million if Novartis exercises a buyout option that […]

A biotech company founded by a Nobel prize winner has won the go-ahead from European regulators to begin the application process for conditional marketing authorization of a stem cell-based regenerative heart treatment. Conditional approval, if granted, would allow Cardiff-based Cell Therapy to start selling its Heartcel product for regenerating damaged areas of heart while continuing […]

TiGenix Expands Pipeline And Enters The Cardiology Field With Clinical-Stage Company Acquisition Leuven (BELGIUM) – July 30, 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic adipose-derived stem cells, announced today the acquisition of cardiology-focused cell therapy company Coretherapix S.L., […]